Skip to main content
. Author manuscript; available in PMC: 2022 Feb 16.
Published in final edited form as: Circulation. 2021 Jan 27;143(7):661–672. doi: 10.1161/CIRCULATIONAHA.120.051558

Table 3.

Adverse events by sex (drug therapy)

Male Patients Receiving Drug (n = 687) Female Patients Receiving Drug (n = 405)
Event n (%)* n (%)*
 Hyper- or hypothyroidism 12 (1.7) 6 (1.5)
 Major proarrhythmic event (VT, VF) 8 (1.2) 2 (0.5)
 Allergic reaction 3 (0.4) 4 (1.0)
 Gastrointestinal abnormality excluding moderate/severe diarrhea 3 (0.4) 7 (1.7)
 Hypotension 2 (0.3) 1 (0.2)
 Liver injury/failure 1 (0.1) 2 (0.5)
 Atrial proarrhythmic event 1 (0.1) -
 Pulmonary toxicity 1 (0.1) -
 Blindness - -
 Heart failure - -
 Kidney damage - -
 Moderate or severe diarrhea - -
 Renal failure - -
 Severe headache - -
 Torsades des pointes - -
*

n (%) = number (percent) of patients who reported drug-related adverse event. Percent is calculated among patients who have received drug.